Circuit training for bone health: efficacy of the bone-based rotation exercises principle: A pilot study

Purpose: Physical exercise has been shown effective for bone health, across lifespan, if proper characteristics have been ensured during exercise prescription and conduction. The aim of our study was to verify if workout organization, in postmenopausal women, may have a central role in determining the entity of the osteogenic effect of a physical exercise program. Methods: Thirty-two postmenopausal women (mean age 59.35 ± 3.65 years) were eligible for the study. Plasma BAP and CTx-I were collected, and DEXA, anthropometry, dietary habits, and fitness tests have been ascertained before and after their participation in 12-week supervised workouts. One sub-group (TWs-s) was trained according to a traditional workout scheme, while the other sub-group (BBs-s) was trained following a bone-based scheme of exercise rotation. Results: BBs-s significantly increased BAP plasma values (p = 0.004) and Six-Minute Walking Test result (p < 0.001), while TWs-s not. Both the sub-groups significantly increased Flamingo Balance Test (p = 0.05), Plank Position Test (p < 0.001), Handgrip Test (p = 0.004), Squat Test (p < 0.001), and Arm Curl Test (p < 0.001). Conclusions: When bone health is considered, the establishment of the right exercise order, in a circuit training workout, is very important, because it could amplify or delay mechanoreceptor desensitizing. The experimented bone-based scheme of exercise rotation seems able to furnish positive effects on bone, muscle, and aerobic fitness

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type 2 diabetes mellitus. In this observational, real-world, study we aimed to investigate the efficacy of the combination therapy with those two agents over glycemic control. We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy. A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide. We analyzed changes in glycated hemoglobin from baseline to 6 months of follow-up, as well as changes in fasting glycemia, body weight, body mass index, systolic and diastolic pressure, heart rate, creatinine, estimated glomerular filtration rate and albuminuria. Both groups of patients showed an improvement of glycometabolic control after 6 months of treatment; indeed, the treatment with dapagliflozin plus oral semaglutide showed a reduction of glycated hemoglobin of 1.2% as compared to the 0.5% reduction observed in the dapagliflozin alone group. Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure, total cholesterol, LDL and albumin to creatinine ratio, with a high rate (55%) of near-normalization of glycated hemoglobin. Our real world data confirmed the potential of the oral combination therapy dapagliflozin with semaglutide in inducing pharmacological remission of type 2 diabetes mellitus